Clinical Trial Detail

NCT ID NCT02837991
Title A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

clear cell renal cell carcinoma

papillary renal cell carcinoma

Therapies

CDX-014

Age Groups: adult senior

No variant requirements are available.